Clinical studies of topotecan

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 264-271

  Broom, Colin ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; TOPOTECAN;

CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; META ANALYSIS; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL;

EID: 0030482311     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26396.x     Document Type: Conference Paper

References (42)

1. ROWINSKY, E., L. GROCHOW, C. HENDRICKS, et al. 1992. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J. Clin. Oncol. 10: 647-656.
2. VERWEIJ, J., B. LUND, J. BEIGNEN, et al. 1993. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol. 4: 673-678.
3. SALTZ, L., M. SIROTT, C. YOUNG, et al. 1993. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl. Cancer Inst. 85: 1499-1507.
4. TUBERGEN, D., C. PRATT, C. STEWART, et al. 1994. Phase I study of topotecan in children with refractory solid tumors: A pediatric oncology group study. ASCO Proceedings. 13: 167.
5. SLICHENMYER, W., T. CHEN, R. DONEHOWER, et al. 1994. Clinical pharmacology of topotecan in cancer patients with renal or hepatic dysfunction. Proc Am. Soc. Clin. Oncol. 13: 142.
6. HAAS, N., F. LACRETA, J. WALCZAK, et al. 1994. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion. Cancer Res. 54: 1220-1226.
7. PRATT, C. B., C. STEWART, V. M. SANTANA et al. 1994. Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol. 12: 539-543.
8. ROWINSKY, E. K., A. ADJEI, C. Ross et al. 1994. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol. 12: 2193-2203.
9. HOCHSTER, H., L. LIEBES, J. SPEYER, et al. 1994. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J. Clin. Oncol. 12: 553-559.
10. ROTHENBERG, M. L., H. BURRIS, D. ECKARDT, et al. 1993. Phase I/II study of topotecan and cisplatin in patients with non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 12: 156.
11. MILLER, A., J. HARGIS, R. LILENBAUM, et al. 1994. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study. J. Clin. Oncol. 12: 2743-2750.
12. ROWINSKY, E., L. GROCHOW, S. KAUFMANN, et al. 1994. Sequence-dependent effects of topotecan (T) and cisplatin (C) in a phase I and pharmacokinetic (PK) Study. Proc. Am. Soc. Clin. Oncol. 13: 142.
13. SALTZ, L., J. KANOWITZ, G. SCHWARTZ, et al. 1995. Phase I trial of cisplatin (DDP) plus topotecan (T) on a daily X 5 schedule in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 14: 475.
14. MURREN, J., J. FEDELE, S. ANDERSON, et al. 1995. Phase I trial of cyclophosphamide (ctx) and topotecan (tpt) in refractory cancer. Proc. 14: 475.
15. LILENBAUM, R. C., M. J. RATAIN, A. A. MILLER, et al. 1995. Phase I study of paclitaxel and topotecan in patients with advanced tumors: A cancer and leukemia group B study. J. Clin. Oncol. 13: 2230-2237.
16. HOCHSTER, H., J. SPEYER, R. ORATZ, et al. 1995. Phase I study of taxol with 14-day topotecan continuous low-dose infusion. Proc. Am. Soc. Clin. Oncol. 1: 486.
17. ECKARDT, J., H. BURRIS, D. VON HOFF, et al. 1994. Measurement of tumor topoisomerase I and II levels during the sequential administration of topotecan and etoposide. Proc. Am. Soc. Clin. Oncol. 13: 141.
18. TOLCHER, A., J. O'SHAUGHNESSY, R. WEISS, et al. 1994. A Phase I study of topotecan (a topoisomerase I inhibitor) in combination with doxorubicin (A topoisomerase II inhibitor). Proc. Am. Soc. Clin. Oncol. 13: 157.
19. SEITER, K., E. FELDMAN, X. LI, et al. 1994. Phase I clinical and pharmacodynamic study of topotecan and cytosine arabinoside in acute leukemia. Blood 84: 302A.
20. HEIDEMAN, R., J. KUTTESCH, C. STEWART, et al. 1995. A phase I trial of a fixed systemic exposure (AUC) of carboplatin (CARBO) with continuous infusion (CI) topotecan (TOPO) in pediatric solid tumors. Proc. Am. Soc. Clin. Oncol. 14: 447.
21. GRAHAM, M., M. JAHANZEB, C. DRESLER, et al. 1994. Preliminary results of a phase I study of topotecan plus thoracic radiotherapy for locally advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 13: 340.
22. KUDELKA, A., C. EDWARDS, R. FREEDMAN, et al. 1993. A phase II study of topotecan administered intravenously as 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinoma. Eur. J. Cancer 29A: 722.
23. (Also published in Proceedings of the American Society of Clinical Oncology 1993; 12: A821.)
24. ARMSTRONG, D., E. ROWINSKY, R. DONEHOWER, et al. 1995. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. AACR Proc. Am. Assoc. Cancer Res. 14: 275.
25. EISENHAUER, E. A., W. W. TEN BOKKEL HUININK, K. D. SWENERTON, et al. 1994. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J. Clin. Oncol. 12: 308-313.
26. ANONYMOUS. 1995. Taxol®. Physician's Desk Reference. 682. Montvale NJ. Economics Data Production Company.
27. ARDIZZONI, A., P. HANSEN, P. DOMBERNOWSKY, et al. 1995. Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC). ECCO 8.
28. PEREZ-SOLER, R., B. GLISSON, J. LEE, et al. 1995. Phase II study of topotecan in patients with small cell lung cancer (SCLC) refractory to etoposide. Proc. Am. Soc. Cancer Res. 14: 355.
29. SCHILLER, J., & K. KIM. 1994. Phase II study of topotecan in extensive stage small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13: 330.
30. LYNCH, T. J., L. KALISH, G. STRAUSS, et al. 1994. Phase II study of topotecan in metastatic non-small-cell lung cancer. J. Clin. Oncol. 12: 347-352.
31. WEITZ, J. J. 1995. Randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): A North Central Cancer Treatment Group (NCCTG) Trial. Proc. Am. Assoc. Clin. Oncol. 14: 348.
32. PEREZ-SOLER, R., F. V. FOSSELLA, B. S. GLISSON, et al. 1996. Phase II study of topotecan in patients with advanced NSCLC previously untreated with chemotherapy. J. Clin. Oncol. 14: 503-513.
33. ROBERT, D., R. H. WHEELER, D. C. MOLTHROP, et al. 1994. Phase II study of topotecan in advanced head and neck cancer: Identification of an active new agent. Proc. Am. Assoc. Clin. Oncol. 13: 281.
34. CHANG, A. Y., G. GARROW, L. BOROS, et al. 1995. Clinical and laboratory studies of topotecan in breast cancer. Proc. Am. Soc. Clin. Oncol. 14: 105.
35. PRETI, H. A., W. PLUNKETT, A. H. SARRIS, et al. 1996. Preliminary results of a phase II trial of topotecan in patients with relapsing lymphoma. Blood 86(Suppl. 1): Abs. 3268.
36. KRAUT, E. J. CROWLEY, J. WADE, et al. 1996. Evaluation of topotecan in resistant and relapsing multiple myeloma: A Southwest Oncology Group Study. Blood 86 (Suppl. 1): Abs. 726.
37. CREEMERS, G. J., J. WANDERS, T. GAMUCCI, et al. 1995. Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group. Ann. Onol. 6: 844-846.
38. SCHER, R., C. J. LUSCH, GREEN, et al. 1993. Phase II trial of topotecan in advanced pancreatic cancer. Proc. ECCO 7. 29A (Suppl. 6): 542.
39. GIANTONIO, B. J., R. KOSIEROWSKI, H. E. RAMSEY, et al. 1993. Phase II study of topotecan (TT) for hormone-refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 12: A774.
40. EISENHAUER, E. A., N. WAINMAN, G. BOOS, et al. 1994. Phase II trials of topotecan in patients (Pts) with malignant glioma and soft tissue sarcoma. Proc. Am. Soc. Clin. Oncol. 13: 175.
41. BERAN, M., S. O'BRIEN, S. ARBUCK, et al. 1996. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 86 (Suppl. 1): Abs. 1335.
42. SCHELLENS, J., J. ECKARDT, G. CREEMERS, et al. 1995. Pharmacokinetics (PK), clinical pharmacodynamics (PD) and safety of chronic oral topotecan (T) in a phase I study. Proc. Am. Soc. Clin. Oncol. 14: 457.